It has been previously shown that SU-DHL-2 (ABC-DLBCL) cells are more resistant to R-CHOP treatment than are SU-DHL-4 (GCB-DLBCL) cells.48 Our results suggest that DHI might be used to overcome the R-CHOP resistance that arises in ABC-DLBCL cells. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.